



ISOGENICA ANNOUNCES LEADERSHIP APPOINTMENTS TO PROVIDE STRONG FOUNDATION FOR FUTURE GROWTH

**January 13, 2020
Cambridge, UK**

Isogenica today announced that it has made two leadership appointments to extend and accelerate its partnerships and pipeline of therapeutic assets and provide a strong foundation for Isogenica's future growth. William (Bill) Eldridge joins as Senior Director of Alliances and Edward McGowan joins in the newly created role of Senior Director of Antibody Discovery and Development. Both appointments are effective immediately.

Drs Eldridge and McGowan bring a wealth of biotherapeutic discovery and development experience to Isogenica. Bill was most recently Chief Scientific Officer at Cyclogenix where he led the discovery and development of scFv antibodies, Cyclotide scaffolds and VNAR single domains for half-life extension, specific oral availability and blood-brain barrier transfer. Bill was a senior researcher at Isogenica until 2009 and is a co-inventor of Isogenica's CIS Display technology, which has been highly successful for the discovery of antibodies and peptides including Centyrins®. Edward McGowan joins Isogenica from Covance where he was Director of Biopharmaceutical Development. Prior to that Edward took roles of increasing seniority in biologics discovery and development at Ablynx, Ossianix and the International Aids Vaccine Initiative, building a deep knowledge of single domain antibodies in the process.

Drs Eldridge and McGowan join Edward Walker, newly promoted to Senior Director of Antibody Technologies, David Mead, Director of Business Development, and Chief Executive Emma Sceats in the company's leadership team.

Commenting on these changes Björn Cochlovius, appointed as Isogenica's Chairman in December 2019, said "The new leadership team will support delivery of Isogenica's vision to become the pre-eminent single domain biotherapeutics company, improving patient outcomes via better targeting of chemotherapies and through the development of single domain bispecifics as off-the-shelf alternatives to CAR-T therapies."

The company will be represented at the Biotech Showcase™ conference in San Francisco (13-15 January 2020) by Chairman Björn Cochlovius, Chief Executive Emma Sceats and David Mead, Business Development.

ENDS



Notes to Editors:

Dr Edward McGowan (left) and Dr Bill Eldridge (right)

About Isogenica

Isogenica is an antibody discovery biotechnology company specializing in single domain biotherapeutics. Working in collaboration with biopharmaceutical partners over the last decade the company has developed a deep pipeline including one clinical stage asset and eleven partnered pre-clinical and discovery stage programmes. Single domains are small format antibodies that can be readily incorporated into gene and cell therapies, antibody-drug conjugates and bi- and multi-specific antibody therapeutics making them a highly versatile platform for drug development. LlamdA™ is Isogenica's proprietary fully synthetic single domain VHH library, built with our precision COLIBRA™ technology to eliminate liabilities and provide biophysically robust therapeutic antibodies. Combined with CIS Display, Isogenica's proprietary antibody display platform which enables the full diversity of the company's massive libraries to be displayed, the company has a unique and proven engine for therapeutic antibody discovery and development.

For more information, visit: www.isogenica.com

Contact:

Mandeep Sehmi, Business Development

T: +44 1799 533 680

E: mandeep.sehmi@isogenica.com

